by John R. Fischer
, Senior Reporter | October 06, 2021
Multinational pharmaceutical producer Merck is set to acquire Acceleron Pharma, a publicly traded biopharmaceutical company, for a total equity value of $11.5 billion.
The acquisition will be completed through a subsidiary of Merck, with Acceleron being bought for $180 a share in cash. The deal is expected to expand Merck’s portfolio beyond its primary cancer drug, KEYTRUDA, by introducing new therapeutics that could help it increase revenue, according to CNBC
What attracted Merck to Acceleron was its expertise and knowledge in the use of the transforming growth factor (TGF)-beta superfamily of proteins, which is known to be a main component in the regulation of cell growth, differentiation and repair. It utilizes this ability in its therapeutic solution, sotatercept, which can potentially improve short-term and long-term clinical outcomes in patients with pulmonary arterial hypertension, a rare disease, according to Rob Davis, chief executive officer and president of Merck.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
“Acceleron’s innovative research has yielded an exciting late-stage candidate that complements and strengthens our growing cardiovascular portfolio and pipeline and holds the potential to build upon Merck’s proud legacy in cardiovascular disease,” he said in a statement.
PAH is a type of high blood pressure that affects blood vessels in the lungs. An investigational product, sotatercept is designed to address the imbalance in the basic metabolic panel and activin signaling in the vascular anatomy that leads to PAH. It is currently being used in a late-stage trial, with Merck seeing it as a multibillion-dollar peak sales opportunity. The acquisition comes as Keytruda, an antibody used in cancer immunotherapy, moves toward the loss of market exclusivity in 2028, reported CNBC.
Merck previously partnered with RefleXion Medical last year to combine KEYTRUDA with RefleXion’s biology-guided radiotherapy (BgRT) system
, which combines anatomical CT and functional PET capabilities for guided personalized radiotherapy to treat multiple late-stage cancers, including non-small cell lung cancer (NSCLC).
The deal also gives Merck access to Acceleron’s REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation recombinant fusion protein approved to treat anemia in certain rare blood disorders. Bristol Myers Squibb is helping to develop and commercialize it as part of a global partnership agreement with Acceleron.
Merck plans to initiate a tender offer to acquire all outstanding shares of Acceleron. Once the tender offer is completed, Merck’s subsidiary will be merged into Acceleron and the remaining shares of common stock for Acceleron will be cancelled and converted into the right to receive the same $180 per share price payable in the tender offer.
The deal is expected to be completed in the fourth quarter of 2021.